- Home
- NVX vs LYEL Comparison
NVX vs LYEL Comparison
Compare NVX & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVX
- LYEL
- Stock Information
- Founded
- NVX 2012
- LYEL 2018
- Country
- NVX Australia
- LYEL United States
- Employees
- NVX N/A
- LYEL N/A
- Industry
- NVX Industrial Machinery/Components
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- NVX Miscellaneous
- LYEL Health Care
- Exchange
- NVX Nasdaq
- LYEL Nasdaq
- Market Cap
- NVX 210.3M
- LYEL 207.7M
- IPO Year
- NVX N/A
- LYEL 2021
- Fundamental
- Price
- NVX $1.23
- LYEL $13.13
- Analyst Decision
- NVX
- LYEL Sell
- Analyst Count
- NVX 0
- LYEL 2
- Target Price
- NVX N/A
- LYEL $15.00
- AVG Volume (30 Days)
- NVX 139.6K
- LYEL 25.5K
- Earning Date
- NVX 01-01-0001
- LYEL 11-06-2025
- Dividend Yield
- NVX N/A
- LYEL N/A
- EPS Growth
- NVX N/A
- LYEL N/A
- EPS
- NVX N/A
- LYEL N/A
- Revenue
- NVX $5,931,433.00
- LYEL $60,000.00
- Revenue This Year
- NVX $135.22
- LYEL N/A
- Revenue Next Year
- NVX $1,647.66
- LYEL N/A
- P/E Ratio
- NVX N/A
- LYEL N/A
- Revenue Growth
- NVX N/A
- LYEL 11.11
- 52 Week Low
- NVX $0.81
- LYEL $7.65
- 52 Week High
- NVX $2.73
- LYEL $32.00
- Technical
- Relative Strength Index (RSI)
- NVX 43.71
- LYEL 67.37
- Support Level
- NVX $1.25
- LYEL $12.59
- Resistance Level
- NVX $1.34
- LYEL $13.50
- Average True Range (ATR)
- NVX 0.08
- LYEL 0.66
- MACD
- NVX -0.02
- LYEL 0.16
- Stochastic Oscillator
- NVX 9.37
- LYEL 87.41
About NVX NOVONIX Limited American Depository Shares
NOVONIX Ltd operates in the lithium-ion battery industry. The company has three operating segments namely Graphite Exploration, Battery Technology, and Battery Materials. Graphite Exploration segment is engaged in the exploration and development of high-grade flake graphite deposits. The Battery Technology segment develops battery cell testing equipment and carries out research and development in battery development. The Battery Materials segment develops and manufactures battery anode materials. The Battery Technology segment generates maximum revenue for the company.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.